Table 3 .
Determinants of persistent or chronic respiratory symptoms at the end of tuberculosis treatment
| Factors | Crude OR (95% CI) | p Value | Adjusted OR (95% CI) | p Value |
|---|---|---|---|---|
| Male sex | 1.31 (0.71 to 2.44) | 0.387 | / | / |
| Age | 1.01 (0.98 to 1.03) | 0.646 | / | / |
| Duration of symptoms >12 weeks | 3.31 (1.29 to 8.50) | 0.013 | 2.91 (1.12 to 7.60) | 0.029 |
| Smoking | 1.68 (0.75 to 3.76) | 0.209 | / | / |
| Previous pulmonary tuberculosis | 1.86 (0.69 to 4.98) | 0.218 | / | / |
| HIV infection | 0.76 (0.39 to 1.51) | 0.439 | / | / |
| Extension of pulmonary lesions >4 zones | 1.48 (0.71 to 3.07) | 0.292 | / | / |
| Cavitary disease | 1.12 (0.57 to 2.20) | 0.751 | / | / |
| Fibrotic lesions | 1.24 (0.59 to 2.62) | 0.571 | / | / |
| FEF25–75% | 2.45 (1.26 to 4.77) | 0.008 | / | / |
| ≥80% | 1 (reference) | / | ||
| 65%–79% | 1.39 (0.61 to 3.13) | 0.433 | / | / |
| <65% | 2.72 (1.33 to 5.54) | 0.006 | 2.22 (1.13 to 4.38) | 0.021 |
FEF25–75%, forced expiratory flow between 25% and 75% of forced vital capacity.